S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals

Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis

$47.00
-3.70 (-7.30%)
(As of 04/12/2024 ET)
Today's Range
$46.81
$50.71
50-Day Range
$43.98
$53.69
52-Week Range
$31.52
$54.98
Volume
786,724 shs
Average Volume
630,014 shs
Market Capitalization
$3.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$91.55

Ultragenyx Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
94.8% Upside
$91.55 Price Target
Short Interest
Bearish
4.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.28
Upright™ Environmental Score
News Sentiment
0.45mentions of Ultragenyx Pharmaceutical in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.64 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.34) to ($5.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.44 out of 5 stars

Medical Sector

102nd out of 923 stocks

Pharmaceutical Preparations Industry

33rd out of 430 stocks

RARE stock logo

About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

RARE Stock Price History

RARE Stock News Headlines

Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.7%
Ultragenyx Pharmaceutical, Inc.
Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Ultragenyx Pharmaceutical Inc.
Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical
RARE Apr 2024 50.000 put
Ultragenyx to Participate at Investor Conferences in March
Barclays Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
See More Headlines
Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
4/13/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RARE
Employees
1,276
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$91.55
High Stock Price Target
$133.00
Low Stock Price Target
$48.00
Potential Upside/Downside
+94.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-606,640,000.00
Net Margins
-139.70%
Pretax Margin
-140.12%

Debt

Sales & Book Value

Annual Sales
$434.25 million
Book Value
$3.35 per share

Miscellaneous

Free Float
76,704,000
Market Cap
$3.87 billion
Optionable
Optionable
Beta
0.65

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives


RARE Stock Analysis - Frequently Asked Questions

Should I buy or sell Ultragenyx Pharmaceutical stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RARE shares.
View RARE analyst ratings
or view top-rated stocks.

What is Ultragenyx Pharmaceutical's stock price target for 2024?

10 analysts have issued 1-year price targets for Ultragenyx Pharmaceutical's shares. Their RARE share price targets range from $48.00 to $133.00. On average, they expect the company's share price to reach $91.55 in the next year. This suggests a possible upside of 94.8% from the stock's current price.
View analysts price targets for RARE
or view top-rated stocks among Wall Street analysts.

How have RARE shares performed in 2024?

Ultragenyx Pharmaceutical's stock was trading at $47.82 on January 1st, 2024. Since then, RARE shares have decreased by 1.7% and is now trading at $47.00.
View the best growth stocks for 2024 here
.

When is Ultragenyx Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our RARE earnings forecast
.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its quarterly earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.65) by $0.13. The biopharmaceutical company earned $127.39 million during the quarter, compared to analysts' expectations of $119.38 million. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative trailing twelve-month return on equity of 369.54%. The company's quarterly revenue was up 23.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.16) earnings per share.

What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings?

Ultragenyx Pharmaceutical updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $500.0 million-$530.0 million, compared to the consensus revenue estimate of $504.3 million.

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Woodstock Corp (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Camille L Bedrosian, Corazon (Corsee) D Sanders, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Theodore Alan Huizenga and Thomas Richard Kassberg.
View institutional ownership trends
.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RARE) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners